- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07558044
Ketamine Gargle for Pain After Pediatric Tonsillectomy (KET-TONSIL)
Preemptive Topical Ketamine for Post-Tonsillectomy Analgesia: A Randomized, Double-Blind, Placebo-Controlled Trial in Children
Post-tonsillectomy pain in children is a common and clinically significant problem that may lead to poor oral intake, dehydration, and delayed recovery. This study evaluates whether a simple preoperative intervention-gargling with ketamine-can reduce postoperative pain and improve recovery after pediatric adenotonsillectomy.
In this randomized, double-blind, placebo-controlled trial, 420 children aged 4 to 12 years undergoing elective adenotonsillectomy were assigned to receive either a ketamine gargle (40 mg in saline) or a saline placebo prior to anesthesia induction. Pain intensity was measured using the Visual Analog Scale at multiple time points within the first 24 hours after surgery. Secondary outcomes included postoperative bleeding requiring reintervention, analgesic consumption, and adverse events.
The study aims to determine whether topical ketamine provides effective and safe analgesia as part of an opioid-sparing strategy in pediatric airway surgery.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Adenotonsillectomy is one of the most frequently performed surgical procedures in pediatric patients and is associated with significant postoperative pain. Effective analgesia remains challenging due to the need to balance efficacy with safety, particularly avoiding opioid-related respiratory complications. Topical ketamine, a non-competitive NMDA receptor antagonist, has been proposed as a peripheral analgesic strategy capable of reducing nociceptive signaling without significant systemic effects.
This study was designed as a prospective, randomized, double-blind, placebo-controlled trial conducted at a tertiary care center. A total of 420 pediatric patients (ASA I-II, aged 4-12 years) scheduled for elective adenotonsillectomy were enrolled. Participants were randomized in a 1:1 ratio to receive either a ketamine gargle (40 mg diluted in 30 mL saline) or a placebo saline gargle administered 5 minutes before induction of anesthesia.
All patients underwent standardized anesthetic and surgical protocols to minimize confounding variables. Pain intensity was assessed using the Visual Analog Scale at 0, 4, 8, 12, and 24 hours postoperatively. Secondary outcomes included incidence of postoperative hemorrhage requiring surgical reintervention, total rescue analgesic consumption, and adverse events such as nausea, vomiting, sedation, or psychomimetic effects.
The primary objective was to evaluate the analgesic efficacy of preemptive topical ketamine. Secondary analyses explored its potential impact on postoperative morbidity, particularly bleeding events. This study was conducted in accordance with ethical standards and CONSORT guidelines.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
Miranda
-
Caracas, Miranda, Venezuela, 1040
- VERAZA
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Children aged 4-12 years
- ASA physical status I-II
- Scheduled for elective adenotonsillectomy
- Ability to gargle and spit the study solution
Exclusion Criteria:
- Known hypersensitivity to ketamine
- Coagulation disorders
- History of neuropsychiatric disease
- Active upper respiratory tract infection
Exclusion Criteria:
-
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: KETAMINE GROUP
Preoperative gargle with 40 mg ketamine diluted in 30 mL saline, administered 5 minutes before induction of anesthesia.
|
Ketamine gargle at a dose of 40mg diluted in 30 mL of normal saline, administered 5 minutes before induction of anesthesia.
Patients were instructed to gargle the solution for 30 seconds and then expectorate.
Placebo gargle consisting of 30 mL of normal saline, administered 5 minutes before induction of anesthesia.
Patients were instructed to gargle the solution for 30 seconds and then expectorate.
|
|
Experimental: PLACEBO GROUP
Preoperative gargle with 30 mL normal saline administered 5 minutes before induction.
|
Ketamine gargle at a dose of 40mg diluted in 30 mL of normal saline, administered 5 minutes before induction of anesthesia.
Patients were instructed to gargle the solution for 30 seconds and then expectorate.
Placebo gargle consisting of 30 mL of normal saline, administered 5 minutes before induction of anesthesia.
Patients were instructed to gargle the solution for 30 seconds and then expectorate.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postoperative pain intensity
Zeitfenster: 0, 4, 8, 12, and 24 hours postoperatively
|
Pain intensity measured using the Visual Analog Scale (VAS; 0-10) at predefined postoperative time points.
|
0, 4, 8, 12, and 24 hours postoperatively
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postoperative hemorrhage requiring surgical reintervention
Zeitfenster: Within 24 hours postoperatively
|
Incidence of postoperative bleeding requiring return to the operating room for hemostasis.
|
Within 24 hours postoperatively
|
|
Rescue analgesic consumption
Zeitfenster: 24 hours postoperatively
|
Total requirement of additional analgesics (e.g., paracetamol or NSAIDs) within the first 24 hours after surgery.
|
24 hours postoperatively
|
|
Adverse events
Zeitfenster: 24 hours postoperatively
|
Incidence of postoperative nausea and vomiting, sedation, or psychomimetic effects such as hallucinations or dysphoria.
|
24 hours postoperatively
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Schmerzen
- Neurologische Manifestationen
- Postoperative Komplikationen
- Pathologische Prozesse
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Schmerzen, postoperativ
- Organische Chemikalien
- Pharmazeutische Präparate
- Kohlenwasserstoffe
- Cyclohexane
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Anorganische Chemikalien
- Chlorverbindungen
- Kristalloidlösungen
- Isotonische Lösungen
- Lösungen
- Natriumverbindungen
- Chloride
- Salzsäure
- Ketamin
- Salzlösung
- Natriumchlorid
Andere Studien-ID-Nummern
- KET-AT-2024-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .